Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJuan Li

Discussion

Loading...

Member takes

Overview

Observational analysis shows Aponermin improves minimal residual disease in multiple myeloma, indicating a safe bridging therapy before CAR-T cell treatment.

Key Points

  • Aponermin regimen led to minimal residual disease negativity after one cycle, supporting its efficacy as bridging therapy.
  • Monitoring showed the patient experienced only Grade 1 cytokine release syndrome during CAR-T, resolved with NSAIDs.
  • The treatment strategy involved the Aponermin regimen followed by CAR-T infusion, facilitating hematologic recovery and avoiding complications.
  • This finding suggests a well-tolerated treatment option for patients with multiple myeloma facing CAR-T therapy, with manageable safety profiles.

Cite This Study

Juan Li (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e503https://doi.org/10.1182/blood-2025-7534
View Full Paper
Ask AI
Bookmark
Share